113 related articles for article (PubMed ID: 35779906)
1. CYLD expression in endometrial carcinoma and correlation with clinicohistopathological parameters.
Papadatou V; Tologkos S; Tsolou A; Deftereou TE; Liberis A; Trypsianis G; Alexiadis T; Georgiadi K; Alexiadi CA; Nikolaidou C; Lambropoulou M
Taiwan J Obstet Gynecol; 2022 Jul; 61(4):596-600. PubMed ID: 35779906
[TBL] [Abstract][Full Text] [Related]
2. Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma.
Suenaga N; Kuramitsu M; Komure K; Kanemaru A; Takano K; Ozeki K; Nishimura Y; Yoshida R; Nakayama H; Shinriki S; Saito H; Jono H
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31635163
[TBL] [Abstract][Full Text] [Related]
3. Loss of CYLD promotes cell invasion via ALK5 stabilization in oral squamous cell carcinoma.
Shinriki S; Jono H; Maeshiro M; Nakamura T; Guo J; Li JD; Ueda M; Yoshida R; Shinohara M; Nakayama H; Matsui H; Ando Y
J Pathol; 2018 Mar; 244(3):367-379. PubMed ID: 29235674
[TBL] [Abstract][Full Text] [Related]
4. Relationship between clinicopathological characteristics and CYLD expression in patients with cholesteatoma.
Miyake S; Miwa T; Yoneda G; Kanemaru A; Saito H; Minoda R; Orita Y; Saito H; Jono H
PLoS One; 2020; 15(10):e0240216. PubMed ID: 33031450
[TBL] [Abstract][Full Text] [Related]
5. Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial.
Cranston A; Stocken DD; Stamp E; Roblin D; Hamlin J; Langtry J; Plummer R; Ashworth A; Burn J; Rajan N
Trials; 2017 Mar; 18(1):111. PubMed ID: 28270164
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of the Tumor Suppressor CYLD Sensitizes Mice to Breast Cancer Development.
Pseftogas A; Xanthopoulos K; Siasiaridis A; Poutahidis T; Gonidas C; Tsingotjidou A; Hatzivassiliou E; Mosialos G
Anticancer Res; 2024 May; 44(5):1885-1894. PubMed ID: 38677721
[TBL] [Abstract][Full Text] [Related]
7. Cylindromatosis (CYLD) expression and prognosis of endometrial cancer.
Li YT; Yang ST; Wang PH
Taiwan J Obstet Gynecol; 2022 Nov; 61(6):1093-1094. PubMed ID: 36427984
[No Abstract] [Full Text] [Related]
8. Potential role for the tumor suppressor CYLD in brain and notochord development.
Li T; Wang Y; Li D; Zhou J; Zhang B; He X
Thorac Cancer; 2021 Jun; 12(12):1900-1908. PubMed ID: 33982884
[TBL] [Abstract][Full Text] [Related]
9. L1CAM expression in endometrial carcinomas: an ENITEC collaboration study.
van der Putten LJ; Visser NC; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MP; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Amant F; Massuger LF; Pijnenborg JM
Br J Cancer; 2016 Sep; 115(6):716-24. PubMed ID: 27505134
[TBL] [Abstract][Full Text] [Related]
10. Reduced expression of CYLD promotes cell survival and inflammation in gefitinib-treated NSCLC PC-9 cells: Targeting CYLD may be beneficial for acquired resistance to gefitinib therapy.
Yuan Y; Liu L; Wang Y; Liu S
Cell Biol Int; 2020 Sep; 44(9):1911-1918. PubMed ID: 32441799
[TBL] [Abstract][Full Text] [Related]
11. miR-130b regulates the proliferation, invasion and apoptosis of glioma cells via targeting of CYLD.
Xiao ZQ; Yin TK; Li YX; Zhang JH; Gu JJ
Oncol Rep; 2017 Jul; 38(1):167-174. PubMed ID: 28534976
[TBL] [Abstract][Full Text] [Related]
12. CYLD deficiency enhances metabolic reprogramming and tumor progression in nasopharyngeal carcinoma via PFKFB3.
Wang L; Lin Y; Zhou X; Chen Y; Li X; Luo W; Zhou Y; Cai L
Cancer Lett; 2022 Apr; 532():215586. PubMed ID: 35131382
[TBL] [Abstract][Full Text] [Related]
13. MiR-587 acts as an oncogene in non-small-cell lung carcinoma via reducing CYLD expression.
Li XJ; Chen LW; Gao P; Jia YJ
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12741-12747. PubMed ID: 33378022
[TBL] [Abstract][Full Text] [Related]
14. Cleaved caspase-3 expression is a potential prognostic factor for endometrial cancer with positive peritoneal cytology.
Ogane N; Yasuda M; Kato H; Kato T; Yano M; Kameda Y; Kamoshida S
Cytopathology; 2018 Jun; 29(3):254-261. PubMed ID: 29626374
[TBL] [Abstract][Full Text] [Related]
15. Cylindromatosis Is Required for Survival of a Subset of Melanoma Cells.
La T; Jin L; Liu XY; Song ZH; Farrelly M; Feng YC; Yan XG; Zhang YY; Thorne RF; Zhang XD; Teng L
Oncol Res; 2020 Sep; 28(4):385-398. PubMed ID: 32252875
[TBL] [Abstract][Full Text] [Related]
16. L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer.
Pasanen A; Tuomi T; Isola J; Staff S; Bützow R; Loukovaara M
Int J Gynecol Cancer; 2016 Oct; 26(8):1465-71. PubMed ID: 27648714
[TBL] [Abstract][Full Text] [Related]
17. MiR-181d inhibits cell proliferation and metastasis through PI3K/AKT pathway in gastric cancer.
Jiang K; Xie LF; Xiao TZ; Qiu MY; Wang WL
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8861-8869. PubMed ID: 31696473
[TBL] [Abstract][Full Text] [Related]
18. CENPV Is a CYLD-Interacting Molecule Regulating Ciliary Acetylated α-Tubulin.
Chiticariu E; Regamey A; Huber M; Hohl D
J Invest Dermatol; 2020 Jan; 140(1):66-74.e4. PubMed ID: 31260673
[TBL] [Abstract][Full Text] [Related]
19. The clinicopathologic significance of the loss of BAF250a (ARID1A) expression in endometrial carcinoma.
Zhang ZM; Xiao S; Sun GY; Liu YP; Zhang FH; Yang HF; Li J; Qiu HB; Liu Y; Zhang C; Kang S; Shan BE
Int J Gynecol Cancer; 2014 Mar; 24(3):534-40. PubMed ID: 24557437
[TBL] [Abstract][Full Text] [Related]
20. Nuclear expression of the deubiquitinase CYLD is associated with improved survival in human hepatocellular carcinoma.
Welte S; Urbanik T; Elßner C; Kautz N; Koehler BC; Waldburger N; Bermejo JL; Pinna F; Weiss KH; Schemmer P; Jaeger D; Longerich T; Breuhahn K; Schulze-Bergkamen H
PLoS One; 2014; 9(10):e110591. PubMed ID: 25329885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
